Edgar Filing: Jazz Pharmaceuticals plc - Form 4

Jazz Pharma Form 4 April 15, 20	ceuticals plc							
FORM	П Л					OMB AF	PROVAL	
	UNITED STAT	Washington, D.C. 20549					3235-0287	
Check th if no long subject to Section 1 Form 4 c Form 5 obligatio may con	statement statement	STATEMENT OF CHANGES IN BENEFICIAL OWN SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange ection 17(a) of the Public Utility Holding Company Act of				burden hour response	Estimated average burden hours per	
See Instr 1(b).	200	h) of the Investmen	nt Compa	ny Act of 194	40			
(Print or Type]	Responses)							
1. Name and Address of Reporting Person _2. IssueSmith Karen L.Symbol			nd Ticker o		5. Relationship of Reporting Person(s) to Issuer			
	(First) (Middle)	Jazz Pharmaceu	-		(Check all applicable)			
(Last) CONNAUC BURLING	3. Date of Earliest (Month/Day/Year) 04/13/2016	Transaction	I	Director 10% Owner X_ Officer (give title Other (specify below) Global Head of R&D and CMO				
(Street) 4. If Ame Filed(Mor			Date Origin ear)	al	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
DUBLIN 4,	, L2				Form filed by M Person			
(City)	(State) (Zip)	Table I - Non	-Derivative	e Securities Acq	uired, Disposed of,	, or Beneficial	y Owned	
1.Title of Security (Instr. 3)	any		Date, if Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5)			6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Ordinary			Amount	\$	Reported Transaction(s) (Instr. 3 and 4)			
Shares	04/13/2016	F <u>(1)</u>	103	D [†] 147.34	13,040	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Jazz Pharmaceuticals plc - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration D (Month/Day/ e	5. Date Exercisable and Expiration Date Month/Day/Year)		le and int of rlying ities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owna Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Smith Karen L. CONNAUGHT HOUSE, 1 BURLINGTON RD, FL. 4 DUBLIN 4, L2			Global Head of R&D and CMO			
Signatures						
By: /s/ Valerie Pierce as attorney in fact For: Karen Le Smith	esley	04/1	5/2016			
<u>**</u> Signature of Reporting Person			Date			
Explanation of Poononcool						

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.